Entrepôts, Représentation et Ingénierie des Connaissances
Publications du laboratoire

Recherche approfondie

par Année
par Auteur
par Thème
par Type
--------------------
- Clinicians' adherence versus non adherence to practice guidelines in the management of patients with sarcoma: a cost-effectiveness assessment in two European regions. doi link

Auteur(s): Perrier Lionel(Corresp.), Buja Alessandra, Mastrangelo Giuseppe, Vecchiato Antonella, Sandonà Paolo, Ducimetière Françoise, Blay Jean-Yves, Gilly François, Siani C., Biron Pierre, Ranchère-Vince Dominique, Decouvelaere Anne-Valérie, Thiesse Philippe, Bergeron Christophe, Dei Tos Angelo, Coindre Jean-Michel, Rossi Carlo, Ray-Coquard Isabelle

(Article) Publié: Bmc Health Services Research, vol. 12 p.82 (2012)


Ref HAL: inserm-00711845_v1
PMID 22455759
DOI: 10.1186/1472-6963-12-82
Résumé:

ABSTRACT: BACKGROUND: Although the management of sarcoma is improving, non adherence to clinical practice guidelines (CPGs) remains high, mainly because of the low incidence of the disease and the variety of histological subtypes. Since little is known about the health economics of sarcoma, we undertook a cost-effectiveness analysis (within the CONnective TIssue CAncer NETwork, CONTICANET) comparing costs and outcomes when clinicians adhered to CPGs and when they did not. METHODS: Patients studied had a histological diagnosis of sarcoma, were older than 15 years, and had been treated in the Rhone-Alpes region of France (in 2005/2006) or in the Veneto region of Italy (in 2007). Data collected retrospectively for the three years after diagnosis were used to determine relapse free survival and health costs (adopting the hospital's perspective and a microcosting approach). All costs were expressed in euros at their 2009 value. A 4% annual discount rate was applied to both costs and effects. The incremental cost-effectiveness ratio (ICER) was expressed as cost per relapse-free year gained when management was compliant with CPGs compared with when it was not. To capture uncertainty surrounding ICER, a probabilistic sensitivity analysis was performed based on a non-parametric bootstrap method. RESULTS: A total of 219 patients were included in the study. Compliance with CPGs was observed for 118 patients (54%). Average total costs reached 23,571 euros when treatment was in accordance with CPGs and 27,313 euros when it was not. In relation to relapse-free survival, compliance with CPGs strictly dominates non compliance, i.e. it is both less costly and more effective. Taking uncertainty into account, the probability that compliance with CPGs still strictly dominates was 75%. CONCLUSIONS: Our findings should encourage physicians to increase their compliance with CPGs and healthcare administrators to invest in the implementation of CPGs in the management of sarcoma.